NEWARK, Calif.--(BUSINESS WIRE)--
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company
developing neuromodulators for use in treating aesthetic and therapeutic
conditions, today announced the expansion of its executive leadership
team with the appointment of Caryn McDowell as Senior Vice President,
General Counsel, and Corporate Secretary, effective May 1, 2018. Ms.
McDowell will report to President and Chief Executive Officer Dan
Browne, and will serve as Revance's General Counsel, leading all legal,
governance, and compliance initiatives.
"Caryn brings extensive legal experience in the biopharma and healthcare
sectors, advising companies developing and commercializing novel drug
products," said Mr. Browne. "During her career, she has played a pivotal
role managing a broad range of partnering relationships, strategic
alliances, and financing initiatives critical to the success and growth
of dynamic biotechnology companies. We are pleased to have an
experienced executive join our leadership team as we continue to further
drive the growth of our pipeline, advance our neuromodulator RT002 to
the market, and enhance Revance's value."
Ms. McDowell joins Revance from Cytokinetics, Inc., where she served as
General Counsel, Chief Compliance Officer, and Secretary, and was
instrumental in defining policies and practices for FDA/EMA product
approval and commercialization, as well as managing key alliances and
financing transactions. Previously, she was Vice President, Deputy
General Counsel, and Assistant Secretary at InterMune, Inc., where she
helped prepare for the U.S. approval and launch of Esbriet®
(pirfenidone) and played a leadership role in InterMune's acquisition by
Roche. Earlier in her career, Ms. McDowell served in legal roles of
increasing responsibility at Onyx Pharmaceuticals, Genentech, and
Millennium Pharmaceuticals. Prior to this, she served as Senior Counsel
at the Office of the Inspector General (OIG) U.S. Department of Health
and Human Services and as Assistant Attorney, General Medicaid Fraud
Control Unit of the Commonwealth of Massachusetts.
Ms. McDowell holds a J.D. degree from Boston University School of Law
and a Bachelor of Arts in Political Science and Judaic Studies from the
University of Michigan.
"I look forward to joining the outstanding team at Revance during this
time of rapid growth and development at the company," said Ms. McDowell.
"Revance's innovative work in the neuromodulation field for both
aesthetic and therapeutic treatments is quite impressive, and I am very
excited to contribute to these efforts by leveraging my
commercialization expertise as Revance seeks to move to the next stage
in its transition to a commercial organization."
In connection with Ms. McDowell's appointment, the Compensation
Committee of Revance's Board of Directors has approved the grant of
inducement awards pursuant to Rule 5635(c)(4) of the NASDAQ Listing
Rules. Ms. McDowell's inducement awards consist of a stock option to
purchase 110,000 shares of Revance common stock and 16,000 shares of
restricted Revance common stock. Ms. McDowell's options will vest over a
period of four years, with 25% vesting on the first anniversary of her
first day of employment with Revance and the balance vesting each month
over the remaining three years. Ms. McDowell's restricted stock will
vest over a period of four years starting June 15, 2018, with 25%
vesting on the annual anniversary. These awards are subject to the terms
and conditions of Revance's Amended and Restated 2014 Inducement Plan,
as adopted by the Revance Board of Directors on December 11, 2015. These
awards are effective on Ms. McDowell's first day of employment with
Revance, May 1, 2018, and the exercise price of the options will be the
closing price of Revance common stock on the NASDAQ Global Market on
About Revance Therapeutics, Inc.
Revance Therapeutics is a biotechnology company developing
neuromodulators for use in treating aesthetic and underserved
therapeutic conditions, including muscle movement disorders and pain.
The company's lead drug candidate, DaxibotulinumtoxinA for Injection
(RT002), is currently in development for the treatment of glabellar
lines, cervical dystonia and plantar fasciitis, with plans to initiate
studies in upper limb spasticity and chronic migraine. RT002 has the
potential to be the first long-acting neuromodulator. Revance has
developed a proprietary, stabilizing excipient peptide technology
designed to create novel, differentiated therapies. The company has a
comprehensive pipeline based upon its peptide technology, including
injectable and topical formulations of daxibotulinumtoxinA. More
information on Revance may be found at www.revance.com.
"Revance Therapeutics" and the Revance logo are registered trademarks
of Revance Therapeutics, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180501006505/en/
Jeanie Herbert, 714-325-3584
Ami Bavishi, 212-213-0006
Mariann Caprino, 917-242-1087
Nadine Tosk, 504-453-8344
Source: Revance Therapeutics, Inc.
News Provided by Acquire Media